Trial · NCT03011372
Adverse events190
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 190
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal distension | Gastrointestinal disorders | Pemigatinib 13.5 mg | 3 | 47 | 6 |
| other | Abdominal pain | Gastrointestinal disorders | Pemigatinib 13.5 mg | 16 | 47 | 25 |
| other | Abdominal pain upper | Gastrointestinal disorders | Pemigatinib 13.5 mg | 7 | 47 | 9 |
| other | Acute kidney injury | Renal and urinary disorders | Pemigatinib 13.5 mg | 3 | 47 | 5 |
| other | Ageusia | Nervous system disorders | Pemigatinib 13.5 mg | 6 | 47 | 7 |
| other | Alanine aminotransferase increased | Investigations | Pemigatinib 13.5 mg | 6 | 47 | 11 |
| other | Alopecia | Skin and subcutaneous tissue disorders | Pemigatinib 13.5 mg | 26 | 47 | 29 |
| other | Anaemia | Blood and lymphatic system disorders | Pemigatinib 13.5 mg | 16 | 47 | 27 |
| other | Anxiety | Psychiatric disorders | Pemigatinib 13.5 mg | 5 | 47 | 7 |
| other | Aphthous ulcer | Gastrointestinal disorders | Pemigatinib 13.5 mg | 3 | 47 | 3 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Pemigatinib 13.5 mg | 10 | 47 | 20 |
| other | Aspartate aminotransferase increased | Investigations | Pemigatinib 13.5 mg | 6 | 47 | 10 |
| other | Asthenia | General disorders | Pemigatinib 13.5 mg | 10 | 47 | 12 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Pemigatinib 13.5 mg | 7 | 47 | 14 |
| other | Blepharitis | Eye disorders | Pemigatinib 13.5 mg | 4 | 47 | 4 |
| other | Blood alkaline phosphatase increased | Investigations | Pemigatinib 13.5 mg | 11 | 47 | 14 |
| other | Blood creatinine increased | Investigations | Pemigatinib 13.5 mg | 8 | 47 | 11 |
| other | Bronchitis | Infections and infestations | Pemigatinib 13.5 mg | 3 | 47 | 3 |
| other | COVID-19 | Infections and infestations | Pemigatinib 13.5 mg | 3 | 47 | 3 |
| other | Candida infection | Infections and infestations | Pemigatinib 13.5 mg | 3 | 47 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03011372/events